Pediatric Stakeholder Meeting; Request for Comments; Correction, 15017 [2015-06426]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 54 / Friday, March 20, 2015 / Notices
Estimated Total Annual Burden
Hours: 14,505.
In compliance with the requirements
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: OPRE Reports Clearance Officer.
Email address: OPREinfocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.
The Department specifically requests
comments on (a) whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Karl Koerper,
Reports Clearance Officer.
[FR Doc. 2015–06385 Filed 3–19–15; 8:45 am]
BILLING CODE 4184–22–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–0456]
Pediatric Stakeholder Meeting;
Request for Comments; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration is correcting a document
entitled ‘‘Pediatric Stakeholder Meeting;
Request for Comments’’ that appeared in
the Federal Register of February 26,
2015 (80 FR 10493). The document
announced a public meeting seeking
input from patient groups, consumer
groups, regulated industry, academia
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:14 Mar 19, 2015
Jkt 235001
and other interested parties to obtain
any recommendations or information
relevant to the report to Congress that
FDA is required to submit concerning
pediatrics, as outlined in the Food and
Drug Administration Safety and
Innovation Act (FDASIA). The
document was published with the
incorrect docket number. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT: Lisa
Granger, Office of Policy, Planning,
Legislation, and Analysis, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 3330,
Silver Spring, MD 20993, 301–796–
9115.
In the
Federal Register of February 26, 2015,
in FR Doc. 2015–03974, on page 10493,
the following correction is made:
On page 10493, in the first column,
the Docket No. heading, ‘‘[Docket No.
FDA–20115–N–0456]’’ is corrected to
read ‘‘[Docket No. FDA–2015–N–0456]’’.
SUPPLEMENTARY INFORMATION:
Dated: March 17, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2015–06426 Filed 3–19–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIDDK.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
NATIONAL INSTITUTE OF DIABETES
AND DIGESTIVE AND KIDNEY
DISEASES, including consideration of
personnel qualifications and
performance, and the competence of
PO 00000
Frm 00113
Fmt 4703
Sfmt 4703
15017
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors, NIDDK.
Date: April 15–16, 2015.
Open: April 15, 2015, 8:00 a.m. to 8:15 a.m.
Agenda: Introductions and Overview.
Place: National Institutes of Health,
Building 5, Room 127, 5 Memorial Drive,
Bethesda, MD 20892.
Closed: April 15, 2015, 8:15 a.m. to 6:05
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 5, Room 127, 5 Memorial Drive,
Bethesda, MD 20892.
Closed: April 16, 2015, 8:00 a.m. to 4:30
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 5, Room 127, 5 Memorial Drive,
Bethesda, MD 20892.
Contact Person: Michael W. Krause, Ph.D.,
Scientific Director, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institute of Health, Building 5,
Room B104, Bethesda, MD 20892–1818, (301)
402–4633, mwkrause@helix.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 13, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–06346 Filed 3–19–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
E:\FR\FM\20MRN1.SGM
20MRN1
]]>Agencies
[Federal Register Volume 80, Number 54 (Friday, March 20, 2015)]
[Notices]
[Page 15017]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06426]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-0456]
Pediatric Stakeholder Meeting; Request for Comments; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a document
entitled ``Pediatric Stakeholder Meeting; Request for Comments'' that
appeared in the Federal Register of February 26, 2015 (80 FR 10493).
The document announced a public meeting seeking input from patient
groups, consumer groups, regulated industry, academia and other
interested parties to obtain any recommendations or information
relevant to the report to Congress that FDA is required to submit
concerning pediatrics, as outlined in the Food and Drug Administration
Safety and Innovation Act (FDASIA). The document was published with the
incorrect docket number. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy,
Planning, Legislation, and Analysis, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993,
301-796-9115.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 26,
2015, in FR Doc. 2015-03974, on page 10493, the following correction is
made:
On page 10493, in the first column, the Docket No. heading,
``[Docket No. FDA-20115-N-0456]'' is corrected to read ``[Docket No.
FDA-2015-N-0456]''.
Dated: March 17, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2015-06426 Filed 3-19-15; 8:45 am]
BILLING CODE 4164-01-P
